Incretin based therapies offer new options for Type 2 diabetes
Once daily liraglutide, a new analogue of human GLP-1, provides better glycaemic control than glimepiride in patients with Type 2 diabetes, according to results from the LEAD-3 Mono trial....
Want to read complete article? Please Sign in or Register.